Hana Pharm Co Ltd
KRX:293480
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Hana Pharm Co Ltd
Net Income (Common)
Hana Pharm Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hana Pharm Co Ltd
KRX:293480
|
Net Income (Common)
₩12.7B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Yuhan Corp
KRX:000100
|
Net Income (Common)
₩191.1B
|
CAGR 3-Years
27%
|
CAGR 5-Years
0%
|
CAGR 10-Years
4%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Net Income (Common)
₩267B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Net Income (Common)
₩169.6B
|
CAGR 3-Years
27%
|
CAGR 5-Years
70%
|
CAGR 10-Years
1%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Net Income (Common)
₩5.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-8%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Net Income (Common)
₩20.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Hana Pharm Co Ltd
Glance View
Hana Pharm Co., Ltd. engages in the research, development, and manufacture of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do and currently employs 657 full-time employees. The company went IPO on 2018-10-02. The company’s main products include cardiovascular drugs involves hypertension and hyperlipidemia medicines, as well as blood circulation improvement drugs; analgesics for severe pain and anesthetics for surgery and sedation; as well as gastrointestinal drugs such as peptic ulcer treatment and antispasmodics. The firm also provides antibiotics, dermatology analgesics, antipyretics and anti-inflammatory drugs.
See Also
What is Hana Pharm Co Ltd's Net Income (Common)?
Net Income (Common)
12.7B
KRW
Based on the financial report for Sep 30, 2025, Hana Pharm Co Ltd's Net Income (Common) amounts to 12.7B KRW.
What is Hana Pharm Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-13%
Over the last year, the Net Income (Common) growth was -35%. The average annual Net Income (Common) growth rates for Hana Pharm Co Ltd have been -20% over the past three years , -13% over the past five years .
